ENVALITH
株式会社ステムリム logo

StemRIM Inc.

4599Growth MarketPharmaceuticals

株式会社ステムリム logo
StemRIM Inc.4599

Governance

The Board of Directors is a company with an Audit & Supervisory Board, consisting of 4 directors, of which 2 are outside directors (50% outside director ratio). An executive officer system has been introduced to separate business execution from supervision. The Audit & Supervisory Board consists entirely of 3 outside auditors and generally meets monthly. The securities report does not mention the establishment of a nomination committee or a compensation committee.

Outside Director Ratio

50.0%

Nomination Committee

Not Established

Compensation Committee

Not Established

Risk Management

The Company has established the "Risk Management Regulations," the "Compliance Regulations," and the "Risk and Compliance Operations Manual," and has set up a "Risk and Compliance Committee" chaired by the Representative Director. The Company has built a framework to monitor and manage sustainability-related risks in an integrated manner together with management risks.

Shareholder Returns

Continues its no-dividend policy. The projected annual dividend for FY2026 (ending March 2026) is ¥0. Priority is given to securing funds for R&D, with no dividends planned for the time being. No new disclosures regarding share buybacks.

Dividend Policy

The company prioritizes securing funds to enable continuous and planned execution of R&D activities, and plans not to pay dividends for the time being. The actual annual dividend for FY2025 (ending March 2025) was ¥0, and the projected annual dividend for FY2026 (ending March 2026) is also ¥0. The company will consider distribution of surplus in the future while taking into account its business performance and financial condition.

Dividend

None

Share Buyback

None

Shareholder Benefits

None

ESG

The company positions addressing intractable diseases through the development of Regenerative Inducing Medicine® as its social mission, and has identified six materiality issues. On the human capital front, it achieved a female manager ratio of 54.5% (actual results for FY2025 ending July 2025) and an average annual paid leave uptake of 14.6 days. It is promoting initiatives such as a flextime system, childcare leave programs, and a revamped personnel evaluation system, and has set quantitative targets toward FY2027 (ending July 2027), including a 90% male childcare leave uptake rate. On the environmental front, the company works to reduce CO2 emissions through waste sorting, electricity conservation, and reduction of paper resource use.

Last updated: October 21, 2025